The Intersection of Heart Failure and Iron Deficiency Anemia: Diagnostic and Therapeutic Approaches.

IF 2.4 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Current Cardiology Reviews Pub Date : 2025-01-03 DOI:10.2174/011573403X331380241111091452
Maleesha Bw Thammitage, Naji Moussa, Ali Rezvani, Damandeep Kaur Dhillon, Miryam Lisseth Obando Gamarra, Kanwaraj Singh, Abdul Hawwa, Alejandra Felix Vincente, Sehajpreet Kaur, Kiranmayee Seshasai Nemalapuri, Devika Poonwassie, Manju Rai
{"title":"The Intersection of Heart Failure and Iron Deficiency Anemia: Diagnostic and Therapeutic Approaches.","authors":"Maleesha Bw Thammitage, Naji Moussa, Ali Rezvani, Damandeep Kaur Dhillon, Miryam Lisseth Obando Gamarra, Kanwaraj Singh, Abdul Hawwa, Alejandra Felix Vincente, Sehajpreet Kaur, Kiranmayee Seshasai Nemalapuri, Devika Poonwassie, Manju Rai","doi":"10.2174/011573403X331380241111091452","DOIUrl":null,"url":null,"abstract":"<p><p>Iron deficiency anemia (IDA) is highly prevalent among individuals with heart failure (HF), impacting 40-70% of patients and serving as a significant prognostic indicator. Linked with oxidative metabolism and myocardial cell damage, IDA exacerbates HF symptoms, including reduced exercise capacity, diminished quality of life, and heightened cardiovascular morbidity. This review explores the diagnosis, treatment, clinical outcomes, prognostic indicators, and forthcoming challenges associated with IDA in HF patients. Crucially, addressing IDA in HF is critical for enhancing prognosis, including clinical outcomes, quality of life, hospitalizations, and survival rates. While oral iron therapy shows efficacy in reducing mortality and hospitalizations, it falls short in improving exercise capacity and quality of life, often deterring patients due to side effects. In contrast, intravenous (IV) iron therapy is highly effective in enhancing hematological parameters, functional capacity, and reducing HF hospitalizations. Optimizing IV iron dosing based on individual patient characteristics is essential for balancing treatment efficacy and adverse effects. Emphasizing individualized approaches, with IV iron emerging as a superior option, underscores the necessity for ongoing research to refine dosing strategies and explore novel therapies. Compliance remains paramount for positive outcomes with IDA treatment, with oral supplementation being cost-effective and easily accessible. However, parenteral supplementation proves beneficial for patients intolerant to oral therapy. Addressing IDA through tailored interventions, including oral or parenteral supplementation, is pivotal in averting complications and improving outcomes in HF patients. This paper consolidates insights into the diagnosis, treatment, impact, pathophysiology, clinical outcomes, research gaps, and future directions concerning IDA in HF patients, drawing on extensive literature to offer a comprehensive understanding of this critical issue.</p>","PeriodicalId":10832,"journal":{"name":"Current Cardiology Reviews","volume":" ","pages":""},"PeriodicalIF":2.4000,"publicationDate":"2025-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Cardiology Reviews","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/011573403X331380241111091452","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Iron deficiency anemia (IDA) is highly prevalent among individuals with heart failure (HF), impacting 40-70% of patients and serving as a significant prognostic indicator. Linked with oxidative metabolism and myocardial cell damage, IDA exacerbates HF symptoms, including reduced exercise capacity, diminished quality of life, and heightened cardiovascular morbidity. This review explores the diagnosis, treatment, clinical outcomes, prognostic indicators, and forthcoming challenges associated with IDA in HF patients. Crucially, addressing IDA in HF is critical for enhancing prognosis, including clinical outcomes, quality of life, hospitalizations, and survival rates. While oral iron therapy shows efficacy in reducing mortality and hospitalizations, it falls short in improving exercise capacity and quality of life, often deterring patients due to side effects. In contrast, intravenous (IV) iron therapy is highly effective in enhancing hematological parameters, functional capacity, and reducing HF hospitalizations. Optimizing IV iron dosing based on individual patient characteristics is essential for balancing treatment efficacy and adverse effects. Emphasizing individualized approaches, with IV iron emerging as a superior option, underscores the necessity for ongoing research to refine dosing strategies and explore novel therapies. Compliance remains paramount for positive outcomes with IDA treatment, with oral supplementation being cost-effective and easily accessible. However, parenteral supplementation proves beneficial for patients intolerant to oral therapy. Addressing IDA through tailored interventions, including oral or parenteral supplementation, is pivotal in averting complications and improving outcomes in HF patients. This paper consolidates insights into the diagnosis, treatment, impact, pathophysiology, clinical outcomes, research gaps, and future directions concerning IDA in HF patients, drawing on extensive literature to offer a comprehensive understanding of this critical issue.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
心衰和缺铁性贫血的交叉:诊断和治疗方法。
缺铁性贫血(IDA)在心力衰竭(HF)患者中非常普遍,影响40-70%的患者,并作为一个重要的预后指标。IDA与氧化代谢和心肌细胞损伤相关,可加重心衰症状,包括运动能力下降、生活质量下降和心血管发病率升高。这篇综述探讨了心衰患者IDA的诊断、治疗、临床结果、预后指标和即将面临的挑战。至关重要的是,解决心衰IDA对改善预后至关重要,包括临床结果、生活质量、住院率和生存率。虽然口服铁治疗在降低死亡率和住院率方面显示出疗效,但在提高运动能力和生活质量方面却存在不足,往往因副作用而使患者望而却步。相比之下,静脉(IV)铁治疗在提高血液学参数、功能能力和减少心衰住院率方面非常有效。根据患者个体特征优化IV铁剂量对于平衡治疗效果和不良反应至关重要。强调个体化治疗方法,静脉注射铁作为一种更好的选择,强调了不断研究以完善剂量策略和探索新疗法的必要性。依从性对于IDA治疗的积极结果仍然至关重要,口服补充具有成本效益且易于获得。然而,肠外补充证明对口服治疗不耐受的患者有益。通过量身定制的干预措施(包括口服或肠外补充)来解决IDA问题,对于避免心衰患者的并发症和改善预后至关重要。本文整合了对HF患者IDA的诊断、治疗、影响、病理生理学、临床结果、研究空白和未来方向的见解,并利用大量文献对这一关键问题进行了全面的了解。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Current Cardiology Reviews
Current Cardiology Reviews CARDIAC & CARDIOVASCULAR SYSTEMS-
CiteScore
3.70
自引率
10.50%
发文量
117
期刊介绍: Current Cardiology Reviews publishes frontier reviews of high quality on all the latest advances on the practical and clinical approach to the diagnosis and treatment of cardiovascular disease. All relevant areas are covered by the journal including arrhythmia, congestive heart failure, cardiomyopathy, congenital heart disease, drugs, methodology, pacing, and preventive cardiology. The journal is essential reading for all researchers and clinicians in cardiology.
期刊最新文献
Dyspnea and Heart Failure: The Role of the Diaphragm. Exploring the Involvement of New Members of the Interleukin Family in Cardiovascular Disease. A New Mechanism of Supraventricular Tachycardia: Gene Mutation. Unlocking Platelet Mechanisms through Multi-Omics Integration: A Brief Review. Molecular and Functional Significance of Growth Differentiation Factor-15: A Review on Cardiovascular-Kidney-Metabolic Biomarker.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1